PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
57.28
-0.73 (-1.26%)
At close: Sep 5, 2025, 4:00 PM
57.26
-0.02 (-0.03%)
After-hours: Sep 5, 2025, 6:53 PM EDT
PTC Therapeutics Employees
PTC Therapeutics had 939 employees as of December 31, 2024. The number of employees decreased by 116 or -11.00% compared to the previous year.
Employees
939
Change (1Y)
-116
Growth (1Y)
-11.00%
Revenue / Employee
$1,879,584
Profits / Employee
$670,046
Market Cap
4.55B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 939 | -116 | -11.00% |
Dec 31, 2023 | 1,055 | -355 | -25.18% |
Dec 31, 2022 | 1,410 | 233 | 19.80% |
Dec 31, 2021 | 1,177 | 210 | 21.72% |
Dec 31, 2020 | 967 | 206 | 27.07% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PTCT News
- 16 days ago - PTC Therapeutics Stock Is Stuck In A Multi-Year Slump - Benzinga
- 16 days ago - PTC Therapeutics to Participate at Upcoming Investor Conferences - PRNewsWire
- 17 days ago - PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst - Seeking Alpha
- 18 days ago - PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns - Benzinga
- 18 days ago - US FDA declines to approve PTC Therapeutics' rare genetic disorder drug - Reuters
- 18 days ago - PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - PRNewsWire
- 4 weeks ago - PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - PRNewsWire